Guardant Health (GH) is higher today as investors react to renewed attention on positive Phase III SERENA-6 trial results that support the clinical value of Guardant360 CDx in a circulating tumor DNA (ctDNA)-guided approach for breast cancer care, helping detect emerging resistance earlier than radiographic progression. The readthrough improves sentiment around Guardant360’s clinical utility and potential demand tied to precision-therapy workflows.

SERENA-6 is viewed as an important validation point for integrating liquid biopsy into treatment decision-making, which can translate into higher clinical adoption and testing volumes when paired with targeted-therapy use. Any incremental uptake in Guardant360 CDx can support Guardant’s oncology revenue trajectory while the company continues investing in its screening expansion strategy.

Guardant is scheduled to report earnings after the close on Thursday, May 7, 2026, which can amplify day-to-day sensitivity to clinical and commercial updates. Investors will be watching for commentary on 2026 demand trends, the pace of clinical adoption for Guardant360 CDx, and progress on broader access initiatives such as national ordering and collection pathways for Shield through Quest Diagnostics.